The shift from hospital visits to at-home treatments is accelerating, creating massive opportunities for companies that make this transition possible.
Advanced autoinjectors and smart delivery systems are transforming how patients receive life-changing treatments, opening up entirely new markets.
As patients gain more control over their treatment, companies enabling this independence are positioned for significant growth in the expanding healthcare market.
The FDA's approval of an at-home injectable Alzheimer's drug represents a pivotal shift towards self-administered chronic disease treatments. This creates a compelling investment opportunity in the ecosystem of companies enabling decentralised healthcare, from advanced drug delivery systems to patient monitoring technologies.
This group focuses on growth-oriented companies that specialise in making long-term therapies more accessible and less burdensome for patients. The theme captures the transition from hospital-based treatments to at-home care, which could dramatically improve patient adherence and quality of life.
These companies were handpicked by professional analysts for their integral role in the at-home treatment value chain. They include specialists in autoinjectors, pre-filled syringes, patient monitoring technologies, and specialised logistics for temperature-sensitive biologics.
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Market capitalisation breakdown for the At-Home Treatment Revolution basket focused on FDA approval impact.
TNDM: $1.04B
PODD: $23.16B
EMBC: $836.34M
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+4
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
Use the growth calculator to see how much investing in these assets could return over one year.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+192.01%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 192.01% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 13๊ฐ ์ค 11๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
